{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:11:50Z","timestamp":1782187910004,"version":"3.54.5"},"reference-count":179,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1053\/j.semnuclmed.2022.10.002","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T21:05:49Z","timestamp":1666731949000},"page":"18-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Emerging Trends in Radionuclide Imaging of Infection and Inflammation in Pediatrics: Focus on FDG PET\/CT and Immune Reactivity"],"prefix":"10.1053","volume":"53","author":[{"given":"Hedieh","family":"Khalatbari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry L.","family":"Shulkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite T.","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0001","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s40134-020-00367-x","article-title":"Acute findings on FDG PET\/CT: Key imaging features and how to differentiate them from malignancy","volume":"8","author":"Li","year":"2020","journal-title":"Curr Radiology Reports"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0002","doi-asserted-by":"crossref","first-page":"7287","DOI":"10.3390\/ijms23137287","article-title":"Pathophysiological concepts and management of pulmonary manifestation of pediatric inflammatory bowel disease","volume":"23","author":"Schmid","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40124-021-00257-6","article-title":"Current insights into the pathophysiology of multisystem inflammatory syndrome in children","volume":"9","author":"Vella","year":"2021","journal-title":"Curr Pediatrics Reports"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0004","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/j.semnuclmed.2021.06.017","article-title":"FDG-PET\/CT of COVID-19 and other lung infections","volume":"52","author":"Eibschutz","year":"2022","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0005","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jmir.2021.03.002","article-title":"Asymptomatic SARS-CoV-2 infection: Incidental findings on FDG PET\/CT","volume":"52","author":"Martinez","year":"2021","journal-title":"J Medical Imaging Radiat Sci"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0006","first-page":"35","article-title":"Fever of unknown origin\u2013reexamined and redefined","volume":"11","author":"Durac","year":"1991","journal-title":"Curr Clin Top Infect Dis"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0007","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/jpm11020133","article-title":"PET\/CT imaging for personalized management of infectious diseases","volume":"11","author":"Pijl","year":"2021","journal-title":"J Personalized Medicine"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0008","first-page":"1","article-title":"Optimal use of the FDG-PET\/CT in the diagnostic process of fever of unknown origin (FUO): a comprehensive review","author":"Minamimoto","year":"2022","journal-title":"Jpn J Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0009","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cpet.2020.03.002","article-title":"Chamroonrat W: PET\/computed tomography in the evaluation of fever of unknown origin and infectious\/inflammatory disease in pediatric patients","volume":"15","year":"2020","journal-title":"Pet Clin"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0010","doi-asserted-by":"crossref","first-page":"e27929","DOI":"10.1002\/pbc.27929","article-title":"Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO)","volume":"66","author":"Jordan","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0011","doi-asserted-by":"crossref","first-page":"e2842","DOI":"10.1093\/cid\/ciaa1574","article-title":"More evidence is warranted to establish the role of 18FDG-PET\/CT in Fever of Unknown Origin (FUO) investigations among children","volume":"73","author":"Li","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0012","article-title":"Quantifying the contribution of 18F-FDG PET to the diagnostic assessment of pediatric patients with fever of unknown origin: A systematic review and meta-analysis","volume":"1\u201312","author":"Li","year":"2022","journal-title":"Pediatr Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0013","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1007\/s00259-020-04707-z","article-title":"Role of FDG-PET\/CT in children with fever of unknown origin","volume":"47","author":"Pijl","year":"2020","journal-title":"Eur J Nucl Med Mol I"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0014","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ejim.2009.01.002","article-title":"Inflammation of unknown origin versus fever of unknown origin: Two of a kind","volume":"20","author":"Vanderschueren","year":"2009","journal-title":"Eur J Intern Med"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0015","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/165080","article-title":"A Rationale for the use of F18-FDG PET\/CT in fever and inflammation of unknown origin","volume":"2012","author":"Balink","year":"2012","journal-title":"Int J Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0016","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/RLU.0000000000000423","article-title":"Diagnostic utility of 18F-FDG PET\/CT in inflammation of unknown origin","volume":"39","author":"Balink","year":"2014","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0017","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1007\/s00259-015-3010-0","article-title":"18F-FDG PET\/CT in inflammation of unknown origin: A cost-effectiveness pilot-study","volume":"42","author":"Balink","year":"2015","journal-title":"Eur J Nucl Med Mol I"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0018","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/MNM.0000000000000300","article-title":"The predictive value of C-reactive protein and erythrocyte sedimentation rate for 18F-FDG PET&sol;CT outcome in patients with fever and inflammation of unknown origin","volume":"36","author":"Balink","year":"2015","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0019","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3413\/Nukmed-0798-16-02","article-title":"18F-FDG-PET\/CT in unexplained elevated inflammatory markers","volume":"55","author":"Bouter","year":"2016","journal-title":"Nuklearmed"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0020","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1177\/0284185118799512","article-title":"Contribution of 18F-FDG PET\/CT in a case-mix of fever of unknown origin and inflammation of unknown origin: A meta-analysis","volume":"60","author":"Kan","year":"2018","journal-title":"Acta Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0021","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1136\/annrheumdis-2017-212483","article-title":"How useful is PET\/CT in the evaluation of fever\/inflammation of unknown origin? Comment on the article by Sch\u00f6nau et al","volume":"77","author":"Bredemeier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0022","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/annrheumdis-2017-211687","article-title":"The value of 18F-FDG-PET\/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study","volume":"77","author":"Sch\u00f6nau","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0023","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00259-018-4121-1","article-title":"18F-FDGPET\/CT in fever of unknown origin and inflammation of unknown origin: a Chinese multi-center study","volume":"46","author":"Wang","year":"2019","journal-title":"Eur J Nucl Med Mol I"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0024","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijid.2020.01.030","article-title":"Combined clinical parameters improve the diagnostic efficacy of 18F-FDG PET\/CT in patients with fever of unknown origin (FUO) and inflammation of unknown origin (IUO): A prospective study in China","volume":"93","author":"Wang","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0025","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/RHU.0000000000001297","article-title":"Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for the evaluation of patients with inflammation of unknown origin","volume":"27","author":"Salman","year":"2020","journal-title":"Jcr J Clin Rheumatology"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0026","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.3346\/jkms.2021.36.e150","volume":"36","author":"Tsuzuki","year":"2021","journal-title":"J Korean Med Sci"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0027","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/joim.13452","article-title":"Diagnostic performance of 18F-FDG-PET\/CT in inflammation of unknown origin: A clinical series of 317 patients","volume":"291","author":"Holubar","year":"2022","journal-title":"J Intern Med"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0028","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3390\/jcm11020386","article-title":"Diagnostic value of 18F-FDG PET\/CT vs. chest-abdomen-pelvis CT scan in management of patients with fever of unknown origin, inflammation of unknown origin or episodic fever of unknown origin: A comparative multicentre prospective study","volume":"11","author":"Ly","year":"2022","journal-title":"J Clin Medicine"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0029","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1038\/s41598-022-05911-7","article-title":"Diagnostic value of F-18 FDG PET\/CT in fever or inflammation of unknown origin in a large single-center retrospective study","volume":"12","author":"Weitzer","year":"2022","journal-title":"Sci Rep-uk"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0030","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10067-021-05965-4","article-title":"Fluorine-18 labeled fluorodeoxyglucose positron emission tomography\/computed tomography used in diagnosing connective tissue diseases in fever of unknown origin\/inflammatory of unknown origin patients","volume":"41","author":"Chen","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0031","first-page":"e24192","article-title":"The diagnostic value of fluoro-18 fluorodeoxyglucose (F-18 FDG) PET\/CT in fever or inflammation of unknown origin: A retrospective study at a rheumatology clinic","volume":"14","author":"\u00d6\u011f\u00fct","year":"2022","journal-title":"Cureus"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0032","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00043426-199709000-00001","article-title":"Therapy-induced alterations in host defense in children receiving therapy for cancer","volume":"19","author":"Lehrnbecher","year":"1997","journal-title":"J Pediatric Hematology Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0033","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0034","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.71.7017","article-title":"Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update","volume":"35","author":"Lehrnbecher","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0035","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2174\/1573396314666180508121625","article-title":"Febrile neutropenia in children with cancer: approach to diagnosis and treatment","volume":"14","author":"Kebudi","year":"2018","journal-title":"Curr Pediatric Rev"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0036","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1148\/radiographics.19.2.g99mr05283","article-title":"Complications of cancer therapy in children: A radiologist's guide","volume":"19","author":"Parisi","year":"1999","journal-title":"Radiographics"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0037","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/thoraxjnl-2021-217260","article-title":"Infections due to dysregulated immunity: An emerging complication of cancer immunotherapy","volume":"77","author":"Morelli","year":"2022","journal-title":"Thorax"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0038","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/107327481702400212","article-title":"Fever in patients with cancer","volume":"24","author":"Pasikhova","year":"2017","journal-title":"Cancer Control"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0039","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1592\/phco.30.1.57","article-title":"Drug fever","volume":"30","author":"Patel","year":"2010","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0040","article-title":"Simple evaluation of clinical situation and subtypes of pediatric hemophagocytic lymphohistiocytosis by cytokine patterns","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0041","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/MOP.0b013e32834ec9c1","article-title":"Hemophagocytic lymphohistiocytosis","volume":"24","author":"Risma","year":"2012","journal-title":"Curr Opin Pediatr"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0042","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0043","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","article-title":"Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation","volume":"100","author":"Henter","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0044","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjh.13462","article-title":"Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents","volume":"170","author":"Lehmberg","year":"2015","journal-title":"Brit J Haematol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0045","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/art.39332","volume":"68","author":"Ravelli","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0046","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor t-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0047","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood-2017-11-814244","article-title":"Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis","volume":"132","author":"Chinn","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0048","doi-asserted-by":"crossref","first-page":"e27400","DOI":"10.1002\/pbc.27400","article-title":"Limitations of HLH-2004 criteria in distinguishing malignancy-associated hemophagocytic lymphohistiocytosis","volume":"65","author":"Gurunathan","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0049","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/RLU.0b013e3181c7bf20","article-title":"F-18 FDG PET\/CT findings in a case of T-cell lymphoma-associated hemophagocytic syndrome with liver involvement","volume":"35","author":"Suga","year":"2010","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0050","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/10428194.2015.1048442","article-title":"Exploring the role of bone marrow increased FDG uptake on PET\/CT in patients with lymphoma-associated hemophagocytic lymphohistiocytosis: A reflection of bone marrow involvement or cytokine storm?","volume":"57","author":"Yang","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0051","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.semnuclmed.2022.10.002_bib0052","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0053","doi-asserted-by":"crossref","first-page":"E565","DOI":"10.1002\/ajh.24828","article-title":"High prevalence of osteonecrosis among the hemophagocytic lymphohistiocytosis population: Single institution 10-year retrospective data review","volume":"92","author":"Craig","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0054","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s00296-015-3346-6","article-title":"MRI-detected bone marrow changes within 3 weeks after initiation of high-dose corticosteroid therapy: A possible change preceding the subsequent appearance of low-intensity band in femoral head osteonecrosis","volume":"35","author":"Kubo","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0055","first-page":"2015","article-title":"Progressive diffuse osteonecrosis in a patient with secondary hemophagocytic lymphohistiocytosis","volume":"730719","author":"Takahashi","year":"2015","journal-title":"Case Rep Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0056","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.chest.2015.11.004","article-title":"Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis","volume":"149","author":"Seguin","year":"2016","journal-title":"Chest"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0057","doi-asserted-by":"crossref","first-page":"W11","DOI":"10.2214\/AJR.19.21788","article-title":"Hemophagocytic lymphohistiocytosis: A primer for radiologists","volume":"214","author":"Shieh","year":"2020","journal-title":"Am J Roentgenol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0058","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s003300050695","article-title":"Abdominal ultrasound findings in children with hemophagocytic lymphohistiocytosis","volume":"9","author":"Chateil","year":"1999","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0059","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00043426-200106000-00021","article-title":"Bilateral subdural effusions related to disease activity in familial hemophagocytic lymphohistiocytosis in an 8-month-old infant","volume":"23","author":"Zubairu","year":"2001","journal-title":"J Pediatric Hematology Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0060","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00247-003-0894-9","article-title":"Imaging characteristics of hemophagocytic lymphohistiocytosis","volume":"33","author":"Fitzgerald","year":"2003","journal-title":"Pediatr Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0061","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1148\/radiol.2303030223","article-title":"Hemophagocytic lymphohistiocytosis in children: Abdominal US findings within 1 week of presentation","volume":"230","author":"Schmidt","year":"2004","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0062","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1442-200X.2011.03421.x","article-title":"Computed tomography findings of the liver in a neonate with Herpes simplex virus-associated hemophagocytic lymphohistiocytosis","volume":"53","author":"Wada","year":"2011","journal-title":"Pediatr Int"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0063","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2169\/internalmedicine.46.6294","article-title":"Hemophagocytic syndrome associated with fatal veno-occlusive disease in the liver","volume":"46","author":"Nakatsuka","year":"2007","journal-title":"Internal Med"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0064","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/MPH.0b013e31818bba1b","article-title":"False positivity of FDG-PET during hemophagocytic lymphohistiocytosis in a child with Hodgkin lymphoma in remission","volume":"31","author":"Corapcioglu","year":"2009","journal-title":"J Pediatric Hematology Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0065","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1097\/MPH.0000000000000886","article-title":"A case of familial hemophagocytic lymphohistiocytosis type 4 with involvement of the central nervous system complicated with infarct","volume":"39","author":"Ciraci","year":"2017","journal-title":"J Pediatric Hematology Sol Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0066","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-03-2012-6026","article-title":"PET\/CT images of a patient with haemophagocytic lymphohistiocytosis","volume":"2012","author":"Ko\u00e7","year":"2012","journal-title":"Bmj Case Reports"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0067","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00277-013-1906-y","article-title":"Clinical implication of F-18 FDG PET\/CT in patients with secondary hemophagocytic lymphohistiocytosis","volume":"93","author":"Kim","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0068","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.crad.2016.05.011","article-title":"The role of 18F-FDG PET\/CT in the management of patients with secondary haemophagocytic lymphohistiocytosis","volume":"71","author":"Zheng","year":"2016","journal-title":"Clin Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0069","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00432-015-2094-z","article-title":"The significance of pre-therapeutic F-18-FDG PET\u2013CT in lymphoma-associated hemophagocytic lymphohistiocytosis when pathological evidence is unavailable","volume":"142","author":"Wang","year":"2016","journal-title":"J Cancer Res Clin"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0070","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/RLU.0000000000001699","article-title":"18F-FDG superscan caused by extensive bone marrow involvement in hemophagocytic lymphohistiocytosis","volume":"42","author":"Law","year":"2017","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0071","first-page":"1","article-title":"PET-CT in AML-related hemophagocytic lymphohistiocytosis","volume":"59","author":"Boddu","year":"2017","journal-title":"Leukemia Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0072","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/RLU.0000000000001923","article-title":"Epstein-barr virus\u2013associated hemophagocytic lymphohistiocytosis mimicking lymphoma on FDG PET\/CT","volume":"43","author":"Pan","year":"2018","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0073","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/RLU.0000000000002008","article-title":"Is There any potential of FDG PET\/CT in monitoring disease activity in familial hemophagocytic lymphohistiocytosis?","volume":"43","author":"Tang","year":"2018","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0074","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/RLU.0000000000002649","article-title":"EBV-associated T-cell lymphoproliferative disorders demonstrated on FDG PET\/CT in a patient with hemophagocytic lymphohistiocytosis","volume":"44","author":"Hao","year":"2019","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0075","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/RLU.0000000000003724","article-title":"Multiple-organ involvement in familial hemophagocytic lymphohistiocytosis type 2 shown on FDG PET\/CT","volume":"46","author":"Wang","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0076","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4849081","article-title":"18F-FDG PET\/CT for identifying the potential primary diseases and predicting prognosis of secondary hemophagocytic lymphohistiocytosis in children","volume":"2022","author":"Wei","year":"2022","journal-title":"Contrast Media Mol I"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0077","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/RLU.0000000000003663","article-title":"Central nervous system involvement of hemophagocytic lymphohistiocytosis: When 18F-FDG PET\/CT solves a complex diagnostic investigation","volume":"46","author":"Allard","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0078","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3348\/kjr.2007.8.1.78","article-title":"CNS involvement in hemophagocytic lymphohistiocytosis: CT and MR findings","volume":"8","author":"Chung","year":"2006","journal-title":"Korean J Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0079","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1007\/s00247-007-0569-z","article-title":"A spectrum of neuroradiological findings in children with haemophagocytic lymphohistiocytosis","volume":"37","author":"Goo","year":"2007","journal-title":"Pediatr Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0080","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/pbc.22239","article-title":"Frequency and development of CNS involvement in Chinese children with hemophagocytic lymphohistiocytosis","volume":"54","author":"Yang","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0081","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0031-1287788","article-title":"Familial hemophagocytic lymphohistiocytosis in a pediatric patient diagnosed by brain magnetic resonance imaging","volume":"42","author":"van","year":"2011","journal-title":"Neuropediatrics"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0082","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10072-010-0467-2","article-title":"Hemophagocytic lymphohistiocytosis with neurological presentation: MRI findings and a nearly miss diagnosis","volume":"32","author":"Chiapparini","year":"2011","journal-title":"Neurol Sci"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0083","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1212\/WNL.0b013e31824f800a","article-title":"CNS involvement at the onset of primary hemophagocytic lymphohistiocytosis","volume":"78","author":"Deiva","year":"2012","journal-title":"Neurology"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0084","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jocn.2013.03.032","article-title":"Spectrum of imaging appearances in Australian children with central nervous system hemophagocytic lymphohistiocytosis","volume":"21","author":"Guandalini","year":"2014","journal-title":"J Clin Neurosci"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0085","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.clinimag.2015.07.013","article-title":"Central nervous system imaging findings of hemophagocytic syndrome","volume":"39","author":"Anderson","year":"2015","journal-title":"Clin Imag"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0086","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ejpn.2015.04.009","article-title":"Cerebellar swelling due to familial hemophagocytic lymphohistiocytosis: An unusual presentation","volume":"19","author":"Khan","year":"2015","journal-title":"Eur J Paediatr Neuro"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0087","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/pbc.25967","article-title":"A diagnostic dilemma: Similarity of neuroradiological findings in central nervous system hemophagocytic lymphohistiocytosis and aspergillosis","volume":"63","author":"Foley","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0088","doi-asserted-by":"crossref","first-page":"388","DOI":"10.4103\/0972-2327.165458","article-title":"Hemi-meningitis with hemophagocytic lymphohistiocytosis","volume":"19","author":"Kocak","year":"2016","journal-title":"Ann Indian Acad Neur"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0089","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00234-020-02595-6","article-title":"Atypical neuroimaging characteristics of hemophagocytic lymphohistiocytosis in infants: A case series of hemorrhagic brain lesions in the deep grey matter","volume":"63","author":"Pak","year":"2021","journal-title":"Neuroradiology"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.crad.2020.09.009","article-title":"MRI findings of central nervous system involvement in children with haemophagocytic lymphohistiocytosis: Correlation with clinical biochemical tests","volume":"76","author":"Ma","year":"2021","journal-title":"Clin Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0091","first-page":"1248","article-title":"CNS involvement of virus-associated hemophagocytic syndrome: MR imaging appearance","volume":"21","author":"Forbes","year":"2000","journal-title":"Ajnr Am J Neuroradiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0092","first-page":"1312","article-title":"Diffusion-weighted cranial MR imaging findings in a patient with hemophagocytic syndrome","volume":"27","author":"Ozgen","year":"2006","journal-title":"Ajnr Am J Neuroradiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0093","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.jaip.2018.05.031","article-title":"Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of HLH: Consensus statements by the HLH steering committee of the histiocyte society","volume":"6","author":"Ehl","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0094","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bj.2019.09.002","article-title":"Immune checkpoint inhibitors win the 2018 Nobel Prize","volume":"42","author":"Huang","year":"2019","journal-title":"Biomed J"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0095","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nrd1720","article-title":"Elucidating mechanisms of drug-induced toxicity","volume":"4","author":"Liebler","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0096","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"New Engl J Medicine"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0097","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.804597","article-title":"Holistic approach to immune checkpoint inhibitor-related adverse events","volume":"13","author":"Poto","year":"2022","journal-title":"Front Immunol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0098","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: A comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0099","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.crad.2020.12.028","article-title":"The imaging of immunotherapy-related hypophysitis and other pituitary lesions in oncology patients","volume":"76","author":"Lasocki","year":"2021","journal-title":"Clin Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0100","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0101","article-title":"Response criteria for immunotherapy and the radiologic patterns of immune-related adverse events","volume":"146","author":"Elsherif","year":"2021","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0102","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","article-title":"Ipilimumab-induced adrenalitis","volume":"40","author":"Bacanovic","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0103","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.clinimag.2017.12.014","article-title":"Multimodality imaging of endocrine immune related adverse events: a primer for radiologists","volume":"50","author":"Alessandrino","year":"2018","journal-title":"Clin Imag"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0104","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.clinimag.2020.04.007","article-title":"A review of the imaging manifestations of immune check point inhibitor toxicities","volume":"64","author":"Thomas","year":"2020","journal-title":"Clin Imag"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0105","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1148\/rg.2019190036","article-title":"Immune checkpoint inhibitor therapy\u2013related pneumonitis: Patterns and management","volume":"39","author":"Kalisz","year":"2019","journal-title":"Radiographics"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0106","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.chest.2020.11.027","article-title":"Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: A position paper from the fleischner society","volume":"159","author":"Johkoh","year":"2021","journal-title":"Chest"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0107","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1097\/RLU.0000000000001673","article-title":"Ipilimumab-induced organizing pneumonia on 18F-FDG PET\/CT in a patient with malignant melanoma","volume":"42","author":"Raad","year":"2017","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0108","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/RLU.0b013e318248549a","article-title":"Ipilimumab-Induced Colitis on FDG PET\/CT","volume":"37","author":"Lyall","year":"2012","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0109","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1007\/s00261-019-02334-3","article-title":"Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy","volume":"45","author":"Shieh","year":"2020","journal-title":"Abdom Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0110","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1159\/000452403","article-title":"Ipilimumab-induced enteritis without colitis: A new challenge","volume":"9","author":"Messmer","year":"2016","journal-title":"Case Reports Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0111","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/CMR.0000000000000484","article-title":"Enteritis without colitis in patients treated with immune checkpoint inhibitors","volume":"28","author":"Sokal","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0112","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10637-013-9939-6","article-title":"Ipilimumab associated hepatitis: Imaging and clinicopathologic findings","volume":"31","author":"Kim","year":"2013","journal-title":"Invest New Drug"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0113","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/RLU.0000000000000606","article-title":"Ipilimumab-induced hepatitis on 18F-FDG PET\/CT in a patient with malignant melanoma","volume":"40","author":"Raad","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0114","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.crad.2020.11.117","article-title":"Imaging spectrum of adverse events of immune checkpoint inhibitors","volume":"76","author":"Shroff","year":"2020","journal-title":"Clin Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0115","doi-asserted-by":"crossref","first-page":"e858","DOI":"10.1097\/MEG.0000000000002280","article-title":"Immune-related cholangitis induced by immune checkpoint inhibitors: A systematic review of clinical features and management","volume":"33","author":"Pi","year":"2021","journal-title":"Eur J Gastroen Hepat"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0116","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.30189","article-title":"Antiprogrammed Cell Death-1 Immunotherapy-Related Secondary Sclerosing Cholangitis","volume":"69","author":"Ogawa","year":"2019","journal-title":"Hepatology"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0117","doi-asserted-by":"crossref","first-page":"e00560","DOI":"10.1002\/rcr2.560","article-title":"Pembrolizumab-induced secondary sclerosing cholangitis in a non-small cell lung cancer patient","volume":"8","author":"Matsumoto","year":"2020","journal-title":"Respirol Case Reports"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0118","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11523-019-00694-w","article-title":"Immune checkpoint inhibitor-induced pancreatic injury: Imaging findings and literature review","volume":"15","author":"Porcu","year":"2020","journal-title":"Target Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0119","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40425-019-0502-7","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0120","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1097\/RLU.0000000000000940","article-title":"Pancreatitis secondary to anti\u2013programmed death receptor 1 immunotherapy diagnosed by FDG PET\/CT","volume":"40","author":"Alabed","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0121","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1007\/s00259-020-04815-w","article-title":"FDG PET\/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment","volume":"47","author":"Iravani","year":"2020","journal-title":"Eur J Nucl Med Mol I"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0122","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/rheumatology\/kez361","article-title":"An MRI study of immune checkpoint inhibitor\u2013induced musculoskeletal manifestations myofasciitis is the prominent imaging finding","volume":"59","author":"Daoussis","year":"2019","journal-title":"Rheumatology"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0123","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.autrev.2018.05.002","article-title":"Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy","volume":"17","author":"Narv\u00e1ez","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0124","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.38282","article-title":"Drug-associated polymyalgia rheumatica\/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4","volume":"66","author":"Goldstein","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0125","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2214\/AJR.21.26538","article-title":"Imaging of cancer immunotherapy: Response assessment methods, atypical response patterns, and immune-related adverse events, from the ajr special series on imaging of inflammation","volume":"218","author":"Sheikhbahaei","year":"2022","journal-title":"Am J Roentgenol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0126","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40134-017-0256-2","article-title":"Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy","volume":"5","author":"Widmann","year":"2017","journal-title":"Curr Radiology Reports"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0127","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0128","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2217\/imt-2018-0035","article-title":"Atezolizumab-induced sarcoid-like granulomatous reaction in a patient with urothelial cell carcinoma","volume":"10","author":"Mitchell","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0129","article-title":"Case report: Hepatic sarcoid-like reaction associated with checkpoint inhibition in a NSCLC patient and a literature review","volume":"12","author":"Lin","year":"2022","journal-title":"Frontiers Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cpet.2019.08.007","article-title":"18F-fluorodeoxyglucose positron emission tomography\/computed tomography for assessing tumor response to immunotherapy in solid tumors melanoma and beyond","volume":"15","author":"Hicks","year":"2020","journal-title":"Pet Clin"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0131","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1200\/JCO.2011.37.9693","article-title":"Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission","volume":"30","author":"Vogel","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0132","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0133","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1007\/s10072-022-05920-4","article-title":"Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice","volume":"43","author":"Villagr\u00e1n-Garc\u00eda","year":"2022","journal-title":"Neurol Sci"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0134","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/01676830.2014.949792","article-title":"Thyroid-Like Ophthalmopathy in a Euthyroid Patient Receiving Ipilimumab","volume":"33","author":"McElnea","year":"2014","journal-title":"Orbit"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0135","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.549168","article-title":"Bilateral posterior uveitis and retinal detachment during immunotherapy: A case report and literature review","volume":"10","author":"Peng","year":"2020","journal-title":"Frontiers Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0136","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/eye.2017.222","article-title":"Neuro-ophthalmic side effects of molecularly targeted cancer drugs","volume":"32","author":"Bhatti","year":"2018","journal-title":"Eye"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0137","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1080\/09273948.2019.1583347","article-title":"Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies","volume":"28","author":"Noble","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0138","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3348\/kjr.2017.18.1.42","article-title":"Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know","volume":"18","author":"Braschi-Amirfarzan","year":"2017","journal-title":"Korean J Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0139","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2020.109275","article-title":"Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors","volume":"132","author":"Park","year":"2020","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0140","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13181-021-00833-8","article-title":"A review of cancer immunotherapy toxicity: Immune checkpoint inhibitors","volume":"17","author":"Chhabra","year":"2021","journal-title":"J Medical Toxicol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0141","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0142","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2017","journal-title":"Jama Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0143","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: Diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0144","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0145","unstructured":"SERVICES USDOHAH, Health NI of, Institute NC: Common Terminology Criteria for Adverse Events (CTCAE), version 5.0., 2017. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed June 17, 2022."},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0146","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0147","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20200663","article-title":"Abdominal immune-related adverse events: Detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography","volume":"94","author":"Anderson","year":"2021","journal-title":"Br J Radiology"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0148","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00261-019-01935-2","article-title":"Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor","volume":"44","author":"Alessandrino","year":"2019","journal-title":"Abdom Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0149","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2213-8587(13)70031-7","article-title":"Ipilimumab-induced autoimmune adrenalitis","volume":"1","author":"Min","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0150","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthrit Care Res"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0151","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1148\/rg.2017170015","article-title":"Thoracic complications of precision cancer therapies: A practical guide for radiologists in the new era of cancer care","volume":"37","author":"Nishino","year":"2017","journal-title":"Radiographics"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0152","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1007\/s00261-020-02531-5","article-title":"Abdominal CT manifestations of adverse events to immunotherapy: A primer for radiologists","volume":"45","author":"Pourvaziri","year":"2020","journal-title":"Abdom Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0153","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190832","article-title":"Immunotherapy-related adverse effects on 18F-FDG PET\/CT imaging","volume":"93","author":"Gandy","year":"2020","journal-title":"Br J Radiology"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0154","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13244-021-01017-2","article-title":"Imaging side effects and complications of chemotherapy and radiation therapy: A pictorial review from head to toe","volume":"12","author":"Albano","year":"2021","journal-title":"Insights Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0155","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1007\/s00261-020-02896-7","article-title":"Imaging of abdominal and pelvic infections in the cancer patient","volume":"46","author":"Itani","year":"2021","journal-title":"Abdom Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0156","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French Endocrine Society Guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti","year":"2018","journal-title":"Endocr-relat Cancer"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0157","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EC-18-0068","article-title":"Society for endocrinology endocrine emergency guidance: Acute management of the endocrine complications of checkpoint inhibitor therapy","volume":"7","author":"Higham","year":"2018","journal-title":"Endocr Connect"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0158","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0159","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0160","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3747\/co.27.5283","article-title":"Chimeric antigen receptor t cell therapy comes to clinical practice","volume":"27","author":"Wall","year":"2020","journal-title":"Curr Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0161","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00005-018-0507-9","article-title":"Adverse effects associated with clinical applications of CAR engineered T cells","volume":"66","author":"Badieyan","year":"2018","journal-title":"Arch Immunol Ther Ex"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0162","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1148\/rg.210065","article-title":"Imaging primer on chimeric antigen receptor T-cell therapy for radiologists","volume":"42","author":"de","year":"2022","journal-title":"Radiographics"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0163","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2214\/AJR.21.26091","article-title":"CAR T-cell therapy: An update for radiologists","volume":"217","author":"Yoon","year":"2021","journal-title":"Am J Roentgenol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0164","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jcyt.2018.10.003","article-title":"Early positron emission tomography\/computed tomography as a predictor of response after CTL019 chimeric antigen receptor \u2013T-cell therapy in B-cell non-Hodgkin lymphomas","volume":"20","author":"Shah","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0165","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00259-021-05551-5","article-title":"[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies","volume":"49","author":"Cohen","year":"2022","journal-title":"Eur J Nucl Med Mol I"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0166","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1007\/s00259-021-05562-2","article-title":"2-[18F]FDG-PET\/CT for early response and brain metabolic pattern assessment after CAR-T cell therapy in a diffuse large B cell lymphoma patient with ICANS","volume":"49","author":"Paccagnella","year":"2022","journal-title":"Eur J Nucl Med Mol I"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0167","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","article-title":"Role of fluorodeoxyglucose positron emission tomography\/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-hodgkin lymphoma","volume":"25","author":"Wang","year":"2019","journal-title":"Biol Blood Marrow Tr"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0168","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s11307-021-01627-8","article-title":"18F-fluorodeoxyglucose positron emission tomography\/computed tomography following chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"23","author":"Ruff","year":"2021","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0169","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1097\/RLU.0000000000003870","article-title":"Early 18F-FDG PET flare-up phenomenon after CAR T-Cell therapy in lymphoma","volume":"47","author":"Boursier","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0170","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0171","first-page":"212","article-title":"Imaging inflammation with positron emission tomography","volume":"9","author":"Iking","year":"2021","journal-title":"Biomed"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0172","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00247-011-2013-7","article-title":"Functional imaging of infection: Conventional nuclear medicine agents and the expanding role of 18-F-FDG PET","volume":"41","author":"Parisi","year":"2011","journal-title":"Pediatr Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0173","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/j.semnuclmed.2017.11.002","article-title":"Radionuclide imaging of infection and inflammation in children: A review","volume":"48","author":"Parisi","year":"2018","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0174","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1053\/j.semnuclmed.2021.06.007","article-title":"PET\/CT Normal Variants and Pitfalls in Pediatric disorders","volume":"51","author":"Agrawal","year":"2021","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0175","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3390\/diagnostics12040835","article-title":"[18F]FDG PET\/CT in short-term complications of COVID-19: Metabolic markers of persistent inflammation and impaired respiratory function","volume":"12","author":"Trivi\u00f1o-Ib\u00e1\u00f1ez","year":"2022","journal-title":"Diagnostics"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0176","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.jacr.2022.02.017","article-title":"ACR appropriateness criteria\u00ae osteomyelitis or septic arthritis-child (Excluding Axial Skeleton)","volume":"19","author":"Imaging EP on","year":"2022","journal-title":"J Am Coll Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0177","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.rcl.2021.08.012","article-title":"Pediatric musculoskeletal infections imaging guidelines and recommendations","volume":"60","author":"Butt","year":"2022","journal-title":"Radiol Clin N Am"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0178","doi-asserted-by":"crossref","first-page":"025","DOI":"10.1055\/s-0037-1615782","article-title":"Nuclear medicine applications in pediatric musculoskeletal diseases: The added value of hybrid imaging","volume":"22","author":"Parisi","year":"2018","journal-title":"Semin Musculoskel R"},{"key":"10.1053\/j.semnuclmed.2022.10.002_bib0179","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.jacr.2017.01.039","article-title":"ACR appropriateness criteria\u00ae back pain\u2014child","volume":"14","author":"Booth","year":"2017","journal-title":"J Am Coll Radiol"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822000897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822000897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:40:31Z","timestamp":1757544031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299822000897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":179,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0001299822000897"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.10.002","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Trends in Radionuclide Imaging of Infection and Inflammation in Pediatrics: Focus on FDG PET\/CT and Immune Reactivity","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}